摘要
背景:异柠檬酸脱氢酶(IDH)突变启动事件定义主要的神经胶质瘤的临床和预后类,但尚未很好解释的潜在机制。当前的研究的主要目的是为了更好地理解IDH突变的潜在生物学神经胶质瘤是被基因表达谱。 方法:核糖核酸测序数据的年级II-IV神经胶质瘤中国神经胶质瘤的基因图谱(CGGA,N = 325)被用来评估IDH突变体和野生型之间的差异表达基因神经胶质瘤和构建基因表达式分类器来检测IDH突变样品具有高敏感性和特异性。分类器是独立验证RNA从癌症基因组图谱测序数据(TCGA,N = 699)、和预后价值的分类器也评估两个数据集。 结果:58-gene-pair IDH突变签名是由使用最高得分对算法。CGGA数据集,98.5%和100% IDH突变样本还预测基于突变体的基因表达在ii iii、IV神经胶质瘤年级IDH地位,分别。在TCGA数据集,比例分别为99.8%和100%,分别。签名依然在多变量cox分析预后标记TCGA CGGA和数据集。 结论:与典型基因表达的特征,准确地预测IDH突变状态。这表明这些肿瘤并添加预后之间共同的生物学和生物信息不被单独突变状态。这些结果有助于临床试验的数量出现分层。RNA-seq越来越普遍和有效的神经胶质瘤的分子诊断,这种基因签名将提供一个精确的方法来预测IDH RNA-seq数据突变状态。
关键词: 神经胶质瘤
Current Molecular Medicine
Title:Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas
Volume: 17 Issue: 7
关键词: 神经胶质瘤
摘要: Background: Isocitrate dehydrogenase (IDH) mutation is the initiating event that defines major clinical and prognostic classes of gliomas, but the potential mechanisms have not been well interpreted yet. The main objective of the current study was to better understand the underlying biology of IDH mutant gliomas as captured by gene expression profiles.
Methods: RNA sequencing data of WHO grade II-IV gliomas from the Chinese Glioma Genome Atlas (CGGA, N=325) were used to assess differentially expressed genes between IDH mutant and wild type gliomas and to construct a gene expression-based classifier to detect IDH mutant samples with high sensitivity and specificity. The classifier was validated in independent RNA sequencing data from the Cancer Genome Atlas (TCGA, N=699), and the prognostic value of the classifier was also assessed in the two datasets.
Results: A 58-gene-pair IDH mutation signature was developed by using the top scoring pairs algorithm. In CGGA dataset, 98.5% and 100% IDH mutant samples were also predicted to be mutant by gene expression based IDH status in grade II-III and grade IV gliomas, respectively. In TCGA dataset, the proportions were 99.8% and 100%, respectively. The signature remained to be a prognostic marker in multivariate cox analysis both in CGGA and TCGA datasets.
Conclusion: A characteristic gene expression signature is associated with and accurately predicts IDH mutation status. This suggests a common biology between these tumors and adds prognostic and biologic information that is not captured by the mutation status alone. These results may help in population stratification for clinical trials. As RNA-seq is more and more prevalent and cost-effective in glioma molecular diagnosis, this gene signature would provide a precise method to predict IDH mutation status with RNA-seq data.
Export Options
About this article
Cite this article as:
Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas, Current Molecular Medicine 2017; 17 (7) . https://dx.doi.org/10.2174/1566524018666180212151429
DOI https://dx.doi.org/10.2174/1566524018666180212151429 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Current Pharmaceutical Design Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design OIP5-AS1: A Fascinating Long Noncoding RNA in Carcinoma
Current Pharmaceutical Design Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Nano-Enabled Drug Delivery in Cancer Therapy: Literature Analysis Using the MeSH System
Pharmaceutical Nanotechnology Killing Glioma ‘Stem-like’ Cells via Drug-Induced Relocation of Endosomal Urokinase Proteins
Anti-Cancer Agents in Medicinal Chemistry Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets New Technologies for Drug Delivery Across the Blood Brain Barrier
Current Pharmaceutical Design Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent
Current Cancer Drug Targets MiR-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer SW480 Cells <i>via</i> Targeting STAT3
Recent Patents on Anti-Cancer Drug Discovery RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Review of Procedures Used for the Extraction of Anti-Cancer Compounds from Tropical Plants
Anti-Cancer Agents in Medicinal Chemistry Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets Combinatorial Approaches for the Identification of Brain Drug Delivery Targets
Current Pharmaceutical Design